Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference [Accessibility Statement] Skip Navigation--BOSTON, Feb. 20, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 47th Annual Institutional Investors Conference on Monday, March 2, 2026 at 10:25 a.m. ET.The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website ...

Haemonetics Corporation (NYSE:HAE) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. Haemonetics Corporation (HAE) Q3 Performance Prompts Baird Model Update, Price Target Falls to $81 Haemonetics Corporation (NYSE:HAE) is among the most innovative healthcare stocks. TheFly reported on February 6 that Baird lowered its price target for HAE to $81 from $99 while maintaining an Outperform rating. The firm updated its model following the company’s Q3 results and lowered the estimate ...

Aristotle Capital Boston, LLC, an investment advisor, released its fourth-quarter investor letter for “Small Cap Equity Fund”. A copy of the letter can be downloaded here. U.S. small-cap equities reported modest gains in the fourth quarter of 2025. The quarter started as a continuation of the post-Liberation Day risk-on market environment, while it ended on a strong note, driven by a positive macroeconomic backdrop. Attractive valuations, earnings recovery, broadening of the market, and a shift from mega-ca ...

Core Viewpoint - The performance of Haemonetics' international operations is crucial for assessing its financial resilience and growth prospects, especially in the context of a highly interconnected global economy [2][3]. Group 1: Financial Performance Overview - For the quarter ended December 2025, Haemonetics reported total revenue of $338.97 million, reflecting a decline of 2.8% year over year [4]. - The company is projected to achieve total revenue of $1.32 billion for the full year, indicating a fall of 2.6% from the previous year [9]. Group 2: International Revenue Breakdown - Japan contributed $18.14 million, or 5.4% of total revenue, with a surprise increase of +1.87% compared to analyst expectations [5]. - Europe generated $48.28 million, accounting for 14.2% of total revenue, surpassing projections by +6.65% [6]. - Other International regions contributed $1.81 million, making up 0.5% of total revenue, which was a decline of -22.23% from expectations [7]. Group 3: Future Revenue Expectations - Analysts anticipate revenues of $336.54 million for the current fiscal quarter, representing an increase of 1.8% year over year [8]. - Expected revenue contributions for the current quarter are projected to be 5.6% from Japan ($18.94 million), 13.5% from Europe ($45.38 million), and 1.2% from Other International ($3.93 million) [8].

Core Insights - Haemonetics reported third-quarter revenue of $339 million, with a year-to-date revenue of $1.1 billion, reflecting a 1% decline in organic revenue for the quarter but a 2% increase year to date, driven by growth in Blood Management Technologies (BMT) and offset by declines in Interventional Technologies (IVT) [1][4][6] Financial Performance - Adjusted earnings per share (EPS) increased by 10% to $1.31 in the quarter and 11% year to date to $3.67, with full-year adjusted EPS guidance raised to $4.90 to $5.00 per share [2][5] - The company raised its fiscal 2026 revenue guidance to a decline of 1% to 3% (previously 1% to 4%) and increased organic revenue guidance excluding CSL to growth of 8% to 10% (previously 7% to 10%) [2][6] Segment Performance - BMT grew 8% in the quarter and 11% year to date, driven by strong sales in hemostasis management and the adoption of new products like the TEG 6s disposable and heparinase neutralization cartridge [7][11] - IVT revenue declined 12% in the quarter and 8% year to date, primarily due to weaknesses in esophageal cooling and OEM-related challenges [6][8] Cash Flow and Margins - The company generated $74 million in free cash flow for the quarter, with year-to-date free cash flow reaching $165 million, and raised full-year free cash flow guidance to $200 million to $220 million [16][17] - Adjusted gross margin was reported at 60.2% for the quarter, reflecting a 250 basis point improvement year over year, attributed to technology adoption and divestitures [14][15] Strategic Initiatives - Haemonetics acquired Vivasure for $61 million, enhancing its vascular closure portfolio and targeting a market estimated at $300 million [19] - The company emphasized ongoing share gains and pricing benefits from new technology rollouts, with collection volumes exceeding seasonal expectations [17]

Core Viewpoint - Haemonetics Corporation reported strong earnings for Q3, exceeding analyst expectations in both earnings per share and sales figures, despite a subsequent decline in share price [1]. Financial Performance - The company reported quarterly earnings of $1.31 per share, surpassing the analyst consensus estimate of $1.25 per share [1]. - Quarterly sales reached $338.967 million, exceeding the analyst consensus estimate of $331.616 million [1]. - Haemonetics raised its FY2026 adjusted EPS guidance from a range of $4.80-$5.00 to $4.90-$5.00 [1]. Stock Performance - Following the earnings announcement, Haemonetics shares fell by 6%, trading at $61.13 [1]. Analyst Ratings and Price Targets - Barrington Research analyst Michael Petusky maintained an Outperform rating on Haemonetics and raised the price target from $93 to $94 [3]. - Mizuho analyst Anthony Petrone also maintained an Outperform rating but lowered the price target from $90 to $80 [3].

Company Overview - Haemonetics Corporation provides blood management solutions to blood and plasma collectors, hospitals, and healthcare providers globally, offering integrated devices, information management, and consulting services to enhance clinical outcomes in the blood supply chain [11]. Investment Potential - Haemonetics is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating a solid investment potential [12]. - The company has a Growth Style Score of B, forecasting a year-over-year earnings growth of 8.1% for the current fiscal year, with a recent upward revision in earnings estimates [12]. - The Zacks Consensus Estimate for Haemonetics has increased by $0.01 to $4.94 per share, and the company has an average earnings surprise of +6.8% [12]. Recommendation - With a strong Zacks Rank and favorable Growth and VGM Style Scores, Haemonetics is recommended for investors looking for growth opportunities [13].

Core Insights - Haemonetics Corporation (HAE) reported third-quarter fiscal 2026 adjusted earnings per share (EPS) of $1.31, reflecting a year-over-year increase of 10.1% and exceeding the Zacks Consensus Estimate by 3.1% [1][9] - The company's revenues decreased by 2.7% to $339 million, which still surpassed the Zacks Consensus Estimate by 1.4% [2][9] Revenue Breakdown - Plasma segment revenues reached $138.9 million, up 3.5% year over year, with organic growth of 2.8%, driven by strong demand for immunoglobulin [3] - Blood Center revenues fell 19.6% to $56.6 million, although organic growth was 2.8%, supported by international Plasma demand [4] - Hospital revenues slightly decreased by 0.3% to $143.5 million, with a 0.9% decline on an organic basis [4] Margin Performance - Gross profit increased by 4.6% to $202.4 million, with gross margin expanding by 418 basis points to 59.7% due to an 11.9% decline in the cost of sales [6] - Operating profit rose to $79 million, compared to $71.3 million in the prior year, with an operating margin increase of 287 basis points to 23.3% [7][9] Financial Position - At the end of the third quarter, Haemonetics had cash and cash equivalents of $363.4 million, up from $296.4 million at the end of the previous quarter [8] - Long-term debt remained stable at $920 million, and cumulative net cash flow from operating activities increased to $222.3 million from $65.2 million a year ago [8] Guidance - The company now expects fiscal 2026 GAAP revenues to decline by 1-3%, with organic revenue growth anticipated in the range of 0-2% compared to fiscal 2025 [10] - Adjusted EPS guidance for full-year 2026 is set between $4.90 and $5.00, up from the previous range of $4.80 to $5.00 [11] Overall Assessment - Haemonetics demonstrated better-than-expected results in the fiscal third quarter, with earnings and revenues surpassing estimates despite a year-over-year revenue decline [12] - The performance highlights the strength of the company's core businesses, particularly in Blood Management Technologies and Plasma, while targeted actions are planned to improve Interventional Technologies [12][13]

Financial Data and Key Metrics Changes - Third quarter revenue was $339 million, bringing year-to-date revenue to $988 million, with reported revenue reflecting a $153 million impact from last year's portfolio transitions [5][6] - Adjusted earnings per share increased 10% in the quarter to $1.31 and 11% year-to-date to $3.67, indicating strong earnings quality and durability [6][16] - Adjusted gross margin was 60.2% in the third quarter, up 250 basis points year-over-year, and 60.5% year-to-date, up 390 basis points [13][14] - Free cash flow for the third quarter was $74 million, bringing year-to-date free cash flow to $165 million, representing a more than threefold increase compared to the prior year [17][18] Business Line Data and Key Metrics Changes - Hospital revenue was $144 million in the third quarter, down 1% but up 2% year-to-date organically, with strong performance in Blood Management Technologies offsetting softness in Interventional Technologies [6][9] - Blood Management Technologies grew 8% in the quarter and 11% year-to-date, driven by strong sales of TEG 6s disposables and the heparinase neutralization cartridge [6][7] - Interventional Technology revenue declined 12% in the quarter and 8% year-to-date, primarily due to softness in esophageal cooling and OEM-related headwinds [8][9] - Plasma revenue was $139 million, up 3% on a reported basis, with organic growth of 20% in the quarter and 22% year-to-date, driven by share gains and collection volume [9][10] Market Data and Key Metrics Changes - U.S. plasma collections grew in the low double digits in the third quarter, with the company holding approximately 50% global market share [10] - Blood Center revenue was $57 million in the quarter, growing 3% in the quarter and 4% year-to-date organically, driven by international plasma demand [10][11] Company Strategy and Development Direction - The company is focused on returning the Interventional Technologies franchise to sustainable growth in fiscal 2027, with targeted actions underway to strengthen execution [20][21] - The acquisition of Vivasure is expected to enhance the company's leadership in vascular closure, with a $300 million addressable market identified [43][46] - Capital allocation priorities include investing in organic growth, meeting debt obligations, and opportunistically returning cash to shareholders while maintaining balance sheet flexibility [22][46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the plasma business, highlighting strong share gains and favorable market conditions [25][27] - The company anticipates continued margin expansion, although future increments may be smaller than those seen in fiscal 2026 [30][31] - Management remains optimistic about the growth potential in the vascular closure market, particularly with the anticipated MVP XL label expansion [38][59] Other Important Information - The company raised its full-year revenue guidance to a decline of 1%-3%, reflecting improved performance across Plasma, Blood Center, and Blood Management Technologies [11] - Adjusted operating income increased 4% year-to-date to $254 million, with adjusted operating margin expanding 200 basis points to 25.7% [15] Q&A Session Summary Question: Insights on plasma growth and sustainability - Management highlighted strong share gains and collection volume growth, indicating a favorable outlook for plasma in fiscal 2027 [25][27] Question: Margin expectations and challenges in the hospital business - Management acknowledged a sequential decline in adjusted operating margin but expressed confidence in overall margin expansion moving forward [30][31] Question: Updates on the IVT business and competition - Management noted that a significant portion of the decline in IVT was due to specific market dynamics, but they are confident in their strategy to return to growth [36][38] Question: Details on the Vivasure acquisition and market positioning - Management emphasized the strategic importance of Vivasure in enhancing their vascular closure portfolio and outlined a measured approach to its market launch [43][46] Question: Sustainability of blood center growth - Management indicated that while the blood center business has shown positive growth, it is subject to order timing and market conditions [79]

Financial Data and Key Metrics Changes - Third quarter revenue was $339 million, bringing year-to-date revenue to $988 million, with reported revenue reflecting a $153 million impact from last year's portfolio transitions [5][6] - Adjusted earnings per share increased 10% in the quarter to $1.31 and 11% year-to-date to $3.67, indicating strong earnings quality and durability [6][16] - Adjusted gross margin was 60.2% in the third quarter, up 250 basis points year-over-year, and 60.5% year-to-date, up 390 basis points [13][14] - Free cash flow for the third quarter was $74 million, bringing year-to-date free cash flow to $165 million, representing a more than threefold increase compared to the prior year [18][19] Business Line Data and Key Metrics Changes - Hospital revenue was $144 million in the third quarter, down 1% but up 2% year-to-date organically, with blood management technologies growing 8% in the quarter [6][9] - Plasma revenue was $139 million, up 3% on a reported basis, with organic growth excluding CSL at 20% in the quarter [9][10] - Blood Center revenue was $57 million in the quarter, growing 3% and 4% year-to-date organically, driven by international plasma demand [10][11] Market Data and Key Metrics Changes - U.S. plasma collections grew in the low double digits in the third quarter, with the company holding approximately 50% global market share [10] - The vascular closure market is experiencing headwinds from increasing PFA adoption, which is affecting growth rates in the electrophysiology market [58][60] Company Strategy and Development Direction - The company is focused on returning the interventional technologies franchise to sustainable growth in fiscal 2027, with targeted actions underway to strengthen execution [20][21] - The acquisition of Vivisure is expected to enhance the company's position in vascular closure, with a market potential of approximately $300 million [44][48] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the plasma business, citing strong share gains and favorable market conditions [25][27] - The company anticipates continued margin expansion, although future increments may be smaller than those seen in fiscal 2026 [30][32] Other Important Information - The company raised its full-year revenue guidance, expecting a decline of 1%-3% from a previous range of 1%-4% [11] - Cash on hand at the end of the third quarter was $363 million, up 18% since the start of the fiscal year [19] Q&A Session Summary Question: Insights on plasma growth and sustainability - Management highlighted strong share gains and collection volume growth, indicating a favorable outlook for plasma in fiscal 2027 [25][27] Question: Margin outlook and hospital business challenges - Management acknowledged a sequential decline in adjusted operating margin but expressed optimism about stabilization in the hospital business [28][30] Question: IVT business recovery and competition - Management noted that a significant portion of the decline in IVT was due to specific product disruptions, but they are confident in returning to growth [36][38] Question: Vivisure acquisition details - Management emphasized the strategic importance of Vivisure and its potential to enhance the vascular closure portfolio [44][48] Question: Capital deployment strategy - Management outlined a disciplined approach to capital deployment, prioritizing organic growth and debt reduction while maintaining flexibility for future investments [47][48]